BRADLEY, Ill. (WLS) -- Hundreds of workers at a biotech company in Kankakee County went on strike late Wednesday night. Union workers at the CSL Behring plant in Bradley are expected to rally at about ...

The FDA has approved the first hemophilia B gene therapy, a one-time treatment that addresses a root cause of this inherited disorder and potentially eliminates the need for regular infusions that ...

CSL Behring KK has gained approval from Japan's Ministry of Health, Labour and Welfare (MHLW) to manufacture and market subcutaneous (SC) injection 200mg Andembry pens designed to prevent acute ...

SAN FRANCISCO--(BUSINESS WIRE)--In 2023, the life sciences industry experienced a 13% year-over-year increase in digital experiences, outpacing the global average by 5 percentage points, according to ...

Moscow opening reinforces CSL Behring's promise to deliver its world-class therapies to patients with rare and serious diseases around the world. KING OF PRUSSIA, Pa. — 08 December 2015 - Global ...

The Pennsylvania biotech company CSL Behring says it is on track to file for approval of its hemophilia B gene therapy by the end of June after releasing pivotal data showing statistical superiority ...

Company further increases global manufacturing capabilities with production expansions of albumin in Australia and plasma intermediates in U.S. to meet escalating patient demand for innovative ...

KING OF PRUSSIA, Pa., June 12, 2020 /PRNewswire/ -- Global biotherapeutics leader CSL Behring announced today that the company will both attend and sponsor the World Federation of Hemophilia (WFH) ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The two companies first entered into a partnership to co ...

- Deal accelerates the addition of clazakizumab, an anti-IL6 MAB currently in phase III development for treatment of chronic active antibody-mediated rejection, into CSL Behring's portfolio KING OF ...

SIOUX FALLS, S.D.--(BUSINESS WIRE)--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company advancing a new class of immunotherapies, today announced that it has entered into ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. At BIO 2019, happening June 3 to 6 at the Convention Center ...